Medical Use
LARIS® (canakinumab) is a prescription medication administered by your healthcare provider via a subcutaneous injection (just below the skin). It is used to treat several autoinflammatory Periodic Fever Syndromes, including:
- -Cryopyrin-Associated Periodic Syndromes (CAPS) in patients aged 4 years and older, such as:
- -Familial Cold Autoinflammatory Syndrome (FCAS)
- -Muckle-Wells Syndrome (MWS)
- -Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in both adults and children
- -Hyperimmunoglobulin D Syndrome (HIDS), also known as Mevalonate Kinase Deficiency (MKD), in both adults and children
- -Familial Mediterranean Fever (FMF) in both adults and children
Warning & Precautions
Before starting treatment with ILARIS, inform your healthcare provider about all your medical conditions, including if you:
- -Suspect you have or are being treated for an active infection
- -Show symptoms of an infection
- -Have a history of recurrent infections
- -Have a history of low white blood cell counts
- -Have or have had HIV, Hepatitis B, or Hepatitis C
- -Have recently received or are scheduled to receive any vaccinations
Ensure you are up to date with all age-appropriate vaccines before beginning ILARIS treatment. Avoid receiving “live” vaccines during ILARIS treatment and until your healthcare provider confirms your immune system is no longer weakened.
Additionally, inform your healthcare provider if you:
- -Are pregnant or planning to become pregnant, as it is unknown if ILARIS can harm your unborn baby. Notify your healthcare provider immediately if you become pregnant while on ILARIS.
- -Received ILARIS during pregnancy. It is crucial to inform your baby’s healthcare provider before any vaccinations are administered to your baby within 4 to 12 months after your last ILARIS dose.
- -Are breastfeeding or planning to breastfeed, as it is unknown if ILARIS passes into breast milk. Discuss with your healthcare provider the best way to feed your baby while on ILARIS.
Documentation Availability
Documents required to import Ilaris to India?
Ilaris can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Ilaris from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Ilaris®?
The generic name for Ilaris® is canakinumab.
Who manufactures Ilaris®?
Ilaris® is manufactured by Novartis Pharmaceutical Corporation.
Is Ilaris® approved by the FDA?
Yes, Ilaris® received FDA approval in June 2009.
What is the dosage and form of Ilaris®?
Ilaris® is available as a 180 mg powder for solution for injection, supplied in a single-use vial.
How to order Ilaris® online in India?
Ilaris® can be ordered online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
